Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients

Cancer Letters

Volumn 304, Issue 2, 2011, Pages 144-153

  Charpidou, Andriani ^a   Gkiozos, Ioannis ^a   Konstantinou, Marios ^a   Eleftheraki, Anastasia ^a   Demertzis, Panagiotis ^a   Harrington, Kevin ^b   Polyzos, Aris ^c   Syrigos, Kostas N ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Non small cell lung cancer; Prognosis; Serum; Vascular endothelial growth factor (VEGF); Vascular endothelial growth factor receptor (VEGFR); Washing

Indexed keywords

ANTINEOPLASTIC AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MALE; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TRACHEOBRONCHIAL TOILET;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79952736586     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.018     Document Type: Article

References (30)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Scagliotti G.V., De M.F., Rinaldi M., Crino L., Gridelli C., Ricci S., Zhao Y.D., Liepa A.M., Peterson P., Tonato M. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J. Thorac. Oncol. 2009, 4:1568-1571.
3. Scagliotti G.V., Fossati R., Torri V., Crino L., Giaccone G., Silvano G., Martelli M., Clerici M., Cognetti F., Tonato M. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl. Cancer Inst. 2003, 95:1453-1461.
4. Scagliotti G.V., Parikh P., von P.J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., Gatzemeier U., Digumarti R., Zukin M., Lee J.S., Mellemgaard A., Park K., Patil S., Rolski J., Goksel T., de M.F., Simms L., Sugarman K.P., Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008, 26:3543-3551.
5. Dempke W.C., Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur. J. Cancer 2009, 45:1117-1128.
6. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 2001, 280:C1358-C1366.
7. Bonnesen B., Pappot H., Holmstav J., Skov B.G. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer 2009, 66:314-318.
8. Korpanty G., Smyth E., Sullivan L.A., Brekken R.A., Carney D.N. Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp. Biol. Med. (Maywood) 2010, 235:3-9.
9. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29:15-18.
10. Dempke W.C., Suto T., Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010, 67:257-274.
11. Trape J., Buxo J., de Olaguer J.P. Serum concentrations of vascular endothelial growth factor in advanced non-small cell lung cancer. Clin. Chem. 2003, 49:523-525.
12. Dudek A.Z., Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest. 2005, 23:193-200.
13. Crohns M., Saarelainen S., Laine S., Poussa T., Alho H., Kellokumpu-Lehtinen P. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - association of interleukin-8 and VEGF with survival. Cytokine 2010, 50:30-36.
14. Brattstrom D., Bergqvist M., Larsson A., Holmertz J., Hesselius P., Rosenberg L., Brodin O., Wagenius G. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res. 1998, 18:1123-1127.
15. Brattstrom D., Bergqvist M., Wester K., Hesselius P., Ren Z.P., Scheibenpflug L., Wagenius G., Brodin O. Endothelial markers and circulating angiogenic factors and p53 may be potential markers for recurrence in surgically resected non-small cell lung cancer patients. Med. Sci. Monit. 2004, 10:BR331-BR338.
16. Brattstrom D., Bergqvist M., Hesselius P., Larsson A., Wagenius G., Brodin O. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 2004, 43:55-62.
17. Chakra M., Pujol J.L., Lamy P.J., Bozonnat M.C., Quantin X., Jacot W., Daures J.P. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J. Thorac. Oncol. 2008, 3:1119-1126.
18. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin. Chem. 2001, 47:617-623.
19. Webb N.J., Bottomley M.J., Watson C.J., Brenchley P.E. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin. Sci. (Lond.) 1998, 94:395-404.
20. Banks R.E., Forbes M.A., Kinsey S.E., Stanley A., Ingham E., Walters C., Selby P.J. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br. J. Cancer 1998, 77:956-964.
21. Matsuyama W., Hashiguchi T., Mizoguchi A., Iwami F., Kawabata M., Arimura K., Osame M. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000, 118:948-951.
22. Tamura M., Ohta Y., Kajita T., Kimura K., Go T., Oda M., Nakamura H., Watanabe G. Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer. Oncol. Rep. 2001, 8:1097-1102.
23. Blagosklonny M.V. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol. Ther. 2005, 4:1307-1310.
24. Naumnik W., Nilklinska W., Ossolinska M., Chyczewska E. Serum levels of HMGB1, survivin and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem. Cytobiol. 2009, 47:703-709.
25. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl. J. Med. 2006, 355:2542-2550.
26. Kido Y. Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer. Kurume Med. J. 2001, 48:43-47.
27. Beinert T., Binder D., Oehm C., Ziemer S., Priem F., Schweigert M., Stuschke M., Fleischhacker M., Siebert G., Mergenthaler H.G., Werner T.G., Sezer O., Possinger K. Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?. Eur. J. Med. Res. 1999, 4:328-334.
28. Ohta Y., Ohta N., Tamura M., Wu J., Tsunezuka Y., Oda M., Watanabe G. Vascular endothelial growth factor expression in airways of patients with lung cancer: a possible diagnostic tool of responsive angiogenic status on the host side. Chest 2002, 121:1624-1627.
29. Hoar F.J., Lip G.Y., Belgore F., Stonelake P.S. Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFIt-1) in human breast cancer. Int. J. Biol. Mark. 2004, 19:229-235.
30. Aref S., El S.M., Goda T., Fouda M., Al A.H., Abdalla D. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology 2005, 10:131-134.